🇺🇸 Part B: Multiple-dose ATM-AVI, Cohorts 1-4 in United States

Part B: Multiple-dose ATM-AVI, Cohorts 1-4 (part-b-multiple-dose-atm-avi-cohorts-1-4) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

Part B: Multiple-dose ATM-AVI, Cohorts 1-4 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Infectious Disease approved in United States

Frequently asked questions

Is Part B: Multiple-dose ATM-AVI, Cohorts 1-4 approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Part B: Multiple-dose ATM-AVI, Cohorts 1-4 in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does Part B: Multiple-dose ATM-AVI, Cohorts 1-4 cost in United States?

annual_list: USD 80000.00 per year. Final patient cost depends on reimbursement and any patient access scheme.